Astec LifeSciences Reports Strong FY21 Results, Recommends 15% Final Dividend
Astec LifeSciences Limited announced strong financial results for FY 2020-21. Standalone profit increased by 36.28% to ₹6,469.25 lakh, while revenue from operations grew by 6.25% to ₹55,487.21 lakh. The company's Basic Earnings Per Share rose to ₹33.05. The Board recommended a final dividend of 15% (₹1.50 per share), subject to shareholder approval. The company maintains a healthy financial position with a debt-equity ratio of 0.61 and a net worth of ₹308.70 crore. The 27th Annual General Meeting is scheduled for July 28, 2021.

*this image is generated using AI for illustrative purposes only.
Astec LifeSciences Limited , a prominent player in the agrochemicals segment, has announced its audited financial results for the fiscal year 2020-21, showcasing robust growth and improved profitability.
Financial Highlights
The company reported a significant increase in standalone profit for the year ended March 31, 2021. Here are the key financial highlights:
Metric | FY 2020-21 | FY 2019-20 | Change |
---|---|---|---|
Standalone Profit | ₹6,469.25 lakh | ₹4,747.19 lakh | 36.28% |
Revenue from Operations | ₹55,487.21 lakh | ₹52,222.09 lakh | 6.25% |
Basic Earnings Per Share | ₹33.05 | ₹24.27 | 36.18% |
The company's performance demonstrates strong growth, with a 36.28% increase in standalone profit and a 6.25% rise in revenue from operations compared to the previous fiscal year.
Dividend Announcement
In light of the company's strong financial performance, the Board of Directors has recommended a final dividend of 15% (₹1.50 per share of face value ₹10). This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Annual General Meeting
Astec LifeSciences has scheduled its 27th Annual General Meeting for July 28, 2021, where shareholders will have the opportunity to review the company's performance and vote on key matters, including the proposed dividend.
Financial Position
As of the reported period, Astec LifeSciences maintains a healthy financial position:
- Debt-Equity Ratio: 0.61
- Net Worth: ₹308.70 crore
These figures indicate a balanced capital structure and a solid financial foundation for the company.
Industry Context
Astec LifeSciences operates in the agrochemicals segment, a sector crucial for agricultural productivity and food security. The company's growth in revenue and profitability suggests a positive market environment and effective business strategies in this important industry.
The strong financial results and the decision to recommend a dividend reflect the company's commitment to delivering value to its shareholders while maintaining a robust financial position for future growth and investments in the agrochemicals sector.
Historical Stock Returns for Astec Lifesciences
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-0.84% | -2.86% | -6.77% | +10.54% | -31.31% | -27.11% |